United States – Page 5

BIOSECURE Act: Navigating Industry Implications and Future Directions

1 year ago talkbio0Tagged BIOSECURE, Biotechnology, capabilities, CDMOs, Chinese Language, Contract agreement, development aspects, Industry, Manufacture, manufacturing organizations, pharmaceutical imports, Pharmaceutical supply chain resilience, Supply chain disruptions, United States

BIOSECURE Act, Biotechnology industry, Supply chain disruptions, Chinese pharmaceutical imports, U.S. manufacturing capabilities, Contract development and manufacturing organizations (CDMOs), Pharmaceutical supply chain resilience

BIOSECURE Act Clears House Hurdle, Heads to Senate for Vote on Restricting Chinese Biotech Ties

1 year ago talkbio0Tagged BIOSECURE, Biotech Companies, Biotechnology, Chinese Language, Drug Industry, drug supply chain, innovation, National Security, Risk, Senate, United States, US House of Representatives, Voting

BIOSECURE Act, House of Representatives, Senate Vote, Chinese Biotech Companies, National Security Risks, U.S. Pharmaceutical Industry, Biotechnology Innovation, Drug Supply Chain

BioMarin Restricts Roctavian Sales to U.S., Germany, and Italy Amid Stagnant Sales

1 year ago talkbio0Tagged BioMarin, Financial cost, gene therapy, Germany, Hemophilia A, Italy, profitability, Roctavian, United States

BioMarin, Roctavian, hemophilia A gene therapy, U.S., Germany, Italy, sales strategy, profitability, cost reduction

Amber Therapeutics Raises $100M for Closed-Loop Neuromodulation Implant for Urinary Incontinence

2 years ago talkbio0Tagged amber, closed-loop implant, Neurostimulation/modulation, Pelvis, regulatory approval, Structure of pudendal nerve, U.S., United States, Urinary Incontinence

Amber Therapeutics, urinary incontinence, neuromodulation, closed-loop implant, funding, series A round, pelvic pudendal nerve, mixed incontinence, U.S. regulatory approval.